Galectin Therapeutics Inc. appointed Dr. Henry Brem to its Board of Directors effective March 12, 2026. Dr. Brem, an internationally recognized neurosurgeon-scientist and Henry Brem Professor of Neurosurgery at Johns Hopkins University, brings extensive experience in translational medicine and clinical development to support the company's belapectin programs.
Key takeaways
Board appointed Dr. Henry Brem as independent director effective March 12, 2026
Dr. Brem serves as Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at Sidney Kimmel Comprehensive Cancer Center
Dr. Brem previously served as Director of Neurosurgery at Johns Hopkins from 2000 to 2025
Compensation per Company’s standard non-employee director program; no initial committee service
No arrangements or understandings with other persons; no reportable transactions under Item 404(a)